• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Conference Coverage
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Alpha-2 agonists and analgesia (Proceedings)

August 1, 2011
Carolyn McKune, DVM, DACVA

In the veterinary profession, ?-2 adrenergic receptor agonists (?-2 agonists) are either loved or feared; this is often determined by a veterinarian's familiarity with the drug. There is no doubt that ?-2 agonists have complex effects, but understanding ?-2 agonists increase options for analgesic use, as well as sedation.

In the veterinary profession, α-2 adrenergic receptor agonists (α-2 agonists) are either loved or feared; this is often determined by a veterinarian's familiarity with the drug. There is no doubt that α-2 agonists have complex effects, but understanding α-2 agonists increase options for analgesic use, as well as sedation.

There are benefits to incorporating α-2 agonists into regular practice. Firstly, and the focus of this lecture, is the analgesic benefits for the patient. α-2 receptors are found pre and post synaptically in neuronal tissue, such as the dorsal horn of the spinal cord. The analgesic benefits of α-2 agonists are mediated primarily, but not exclusively, at the dorsal horn. The analgesic benefit for the patient is not dependent on the level of sedation, as it appears the level of sedation is actually mediated supraspinally, in the locus ceruleus. However, this supraspinal action of α-2 agonists may also assist in modulation of descending transmission of nociception. This combination of spinal and possibly supraspinal analgesia is a powerful tool. While veterinarians are often employing analgesic drugs in acutely painful situations, such as with a surgery, α-2 agonists have also been useful as adjunctive analgesia for chronic pain conditions, such as cancer. In addition to α-2 agonists' individual actions in pain modulation, these drugs may also work synergistically with opioids to enhance analgesia (Slingsby, Murrell and Taylor 2010).

There are other benefits from these drugs. The level of sedation and muscle relaxation obtained from administration of an α-2 agonist is quite profound. This facilitates performing, as well as providing analgesia, for many minor diagnostic and surgical interventions. They to produce a reliable level of sedation and analgesia in the cat, which limited drugs can do. When used alone, there is relatively little change in the dog or cat's pulmonary function; blood gases remain stable although respiratory rate and minute ventilation may decrease after α-2 agonist administration. This class of drug greatly reduces the amount of other drugs (e.g. induction and inhalants) necessary to maintain anesthesia while providing a balanced technique for anesthesia. They are not controlled and reversible should problems arise.

Advertisement

However, the benefits of an α-2 agonist must be weighed against the detrimental effects the drug. There is a profound impact on the cardiovascular system, with an initial peripherally mediated bradycardia secondary to vasoconstriction. This initial effect is followed by a centrally mediated bradycardia and decrease in cardiac output. The reduction in cardiac output is compounded by the effect of concomitantly administered drugs on the cardiovascular system. For example, opioids can also cause bradycardia; using these drugs in combination, although providing synergistic analgesic, may result in a profound bradycardia.

Other body systems are impacted as well. Visceral α-2 receptor upregulation and inhibition of acetylcholine can decrease gastrointestinal motility and increase sphincter tone. Vomiting is a common gastrointestinal side effect as well. Patients receiving α-2 agonists will often have hyperglycemia secondary to inhibition of insulin. Patients may also urinate more after these drugs.

From a practical standpoint, there are other difficulties that result from an incorporation of an α-2 agonist. Patients may actually become more aggressive with α-2 agonist administration, presumably because of the centrally mediated disinhibition that can occur. Obtaining venous access can be more challenging after administration of an α-2 agonist.

Therefore, the benefit of an α-2 agonist for analgesia is dependent on choosing the right case. We will review in this lecture several case examples that may benefit from the use of α-2 agonists and some cases where these drugs are best avoided.

Reference

Slingsby, L. S., J. C. Murrell & P. M. Taylor (2010) Combination of dexmedetomidine with buprenorphine enhances the antinociceptive effect to a thermal stimulus in the cat compared with either agent alone. Vet Anaesth Analg, 37, 162-70.

Related Content:

Pain Management
Targeting care for senior cats and their caretakers
Targeting care for senior cats and their caretakers
Treating feline arthritis with spectrum of care
Treating feline arthritis with spectrum of care
Assessing pain in pets
Assessing pain in pets

Advertisement

Latest News

Kentucky Humane Society with Louisville Metro Animal Services to host mega adoption event

San Diego Zoo celebrates Andean bear cub twins

Spring’s pet toxins have sprung

IBPSA and Zoundz Music for Pets team up to reduce pet anxiety in pet care facilities

View More Latest News
Advertisement